STOCK TITAN

Affivant to Present Data on AFVT-2101 at 37th Annual Meeting of SITC

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Affivant, a biotechnology company, will present a poster on AFVT-2101 at the 37th Annual Meeting of SITC on November 11, 2022. AFVT-2101 is an Innate Cell Engager designed to target folate receptor alpha on tumors, facilitating immune cell activation for tumor destruction. The poster reports findings that AFVT-2101 effectively binds to CD16A, induces potent antibody-dependent cellular cytotoxicity (ADCC), and shows minimal off-target effects. The study confirms AFVT-2101's potential as a safe and powerful therapy in preclinical settings.

Positive
  • None.
Negative
  • None.

NEW YORK and BASEL, Switzerland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Affivant, a biotechnology company dedicated to developing novel immune-oncology approaches to activate and enable the innate immune system to fight cancer, will present a poster at the 37th Annual Meeting of The Society for Immunotherapy of Cancer (SITC) highlighting preclinical data for AFVT-2101 (previously AFM32).

AFVT-2101 is a tetravalent, bispecific Innate Cell Engager (ICE®) that bridges folate receptor alpha (FRα) on tumor cells with CD16A expressing innate immune cells, to induce potent and selective targeted tumor cell killing. FRα is a tumor-associated antigen which is highly overexpressed on a variety of epithelial tumors.

The following poster will be presented live at SITC on November 11th:

Title: AFVT-2101, an innate immune-cell engager that selectively targets FOLR1 expressing tumor cells to safely harness potent anti-cancer responses

Poster #: 1212

Authors: Ahmad Trad, Michael Tomaszowski, Josef Caslavsky, Robert Freitag, Sudhir Penugonda, Keith Haan, Markus Rohrwild, Daniel O’Shannessy, Jana Siegler, Peter Sandy, Eric Gaukel, Daniela Penston, Zoë Johnson

The poster shows that AFVT-2101 binds selectively to CD16A (both 158V and 158F variants). Physiological levels of competing IgG do not alter binding efficacy. AFVT-2101 induces potent and selective ADCC, even on FRα low expressing cell lines. AFVT-2101 is also shown to induce efficient ADCP in vitro. Co-culture of PBMCs, tumor cells and AFVT-2101 showed concentration-dependent release of pro-inflammatory cytokines (IFNγ, IP-10, TNFα) and minimal off-target cytokine release, confirming a potent but safe in vitro profile of AFVT-2101.

About ICE molecules

Innate Cell Engager (ICE®) molecules are designed to bivalently bind CD16A+ cells of the innate immune system and a tumor associated antigen, inducing potent, tumor-directed cytotoxicity via antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).

About Affivant

Affivant, a Roivant Sciences company, is dedicated to developing novel immune-oncology approaches to activate and enable the innate immune system to fight cancer. Our innovative bi-specific innate cell engagers are designed to target specific patient populations as powerful monotherapies and combination treatments. AFVT-2101 is currently in IND-enabling studies.

For more information, visit www.affivant.com.

Contact:

Zoë Johnson, Chief Scientific Officer
zoe.johnson@affivant.com


FAQ

What is AFVT-2101 and its significance?

AFVT-2101 is an Innate Cell Engager that targets folate receptor alpha on tumor cells, aiming to enhance immune response against cancer.

When and where will the poster on AFVT-2101 be presented?

The poster will be presented live at the 37th Annual Meeting of SITC on November 11, 2022.

What are the key findings about AFVT-2101 from the SITC poster?

The findings show AFVT-2101 selectively binds to CD16A, induces effective ADCC, and maintains a safe in vitro profile with minimal off-target effects.

What type of cancer does AFVT-2101 target?

AFVT-2101 targets epithelial tumors overexpressing folate receptor alpha.

What is the role of Affivant in cancer therapy development?

Affivant focuses on developing innovative immune-oncology therapies, specifically through the use of bispecific innate cell engagers like AFVT-2101.

What is the status of AFVT-2101's clinical development?

AFVT-2101 is currently in IND-enabling studies, preparing for clinical trials.

Roivant Sciences Ltd. Common Shares

NASDAQ:ROIV

ROIV Rankings

ROIV Latest News

ROIV Stock Data

9.05B
503.28M
29.42%
79.46%
6.3%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
HAMILTON HM11